» Articles » PMID: 16596292

Survival Among Patients with Adenocarcinoma of the Pancreas: a Population-based Study (United States)

Overview
Specialties Oncology
Public Health
Date 2006 Apr 6
PMID 16596292
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor-related factors.

Methods: Through the California Cancer Registry (CCR) we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between 1994 and 2000. Demographic, tumor and treatment information was extracted from the CCR, and socioeconomic status (SES) was assigned based on census block group of residence.

Results: A total of 10,612 eligible patients were identified of whom 1674 (15.8%) underwent surgical resection. Patients of lower SES were less likely to undergo resection and somewhat less likely to survive. Median survival was 3.5 months for patients who were not resected and 13.3 months for those who underwent resection. Adjuvant therapy was associated with a decreased risk of death among patients who underwent resection.

Conclusions: This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population. Median survival was shorter than that reported from other series. Race/ethnicity did not have a significant effect on survival. However patients residing in poor neighborhoods were less likely to undergo resection and somewhat less likely to survive this disease.

Citing Articles

Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery.

Park E, Jang J, Byun J, Kim J, Lee S, Kim H Abdom Radiol (NY). 2024; 49(8):2737-2745.

PMID: 38802630 DOI: 10.1007/s00261-024-04299-4.


National Economic Conditions May Impact the Financial Barriers to Travel for Cancer Operations.

Henry L, Li J, Arciero C, von Holzen U, Schwarz R, Jatoi I Ann Surg Open. 2023; 4(1):e236.

PMID: 37600883 PMC: 10431358. DOI: 10.1097/AS9.0000000000000236.


PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies.

Mucileanu A, Chira R, Mircea P Med Pharm Rep. 2022; 94(4):402-410.

PMID: 36105495 PMC: 9389876. DOI: 10.15386/mpr-2116.


Treatment at a high-volume academic research program mitigates racial disparities in pancreatic adenocarcinoma.

Chu Q, Hsieh M, Gibbs J, Wu X J Gastrointest Oncol. 2022; 12(6):2579-2590.

PMID: 35070389 PMC: 8748054. DOI: 10.21037/jgo-20-584.


Iron Oxide Nanoparticle-Based Hyperthermia as a Treatment Option in Various Gastrointestinal Malignancies.

Palzer J, Eckstein L, Slabu I, Reisen O, Neumann U, Roeth A Nanomaterials (Basel). 2021; 11(11).

PMID: 34835777 PMC: 8622891. DOI: 10.3390/nano11113013.